[HTML][HTML] 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2023
NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2023 - ncbi.nlm.nih.gov
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …
ADA's current clinical practice recommendations and is intended to provide the components …
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association - Diabetes care, 2019 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
ADA's current clinical practice recommendations and is intended to provide the components …
ADA's current clinical practice recommendations and is intended to provide the components …
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association - Diabetes care, 2021 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
the ADA's current clinical practice recommendations and is intended to provide the …
the ADA's current clinical practice recommendations and is intended to provide the …
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association - Diabetes care, 2020 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
the ADA's current clinical practice recommendations and is intended to provide the …
the ADA's current clinical practice recommendations and is intended to provide the …
Development of SGLT1 and SGLT2 inhibitors
T Rieg, V Vallon - Diabetologia, 2018 - Springer
Sodium–glucose cotransporters SGLT1 (encoded by SGLT1, also known as SLC5A1) and
SGLT2 (encoded by SGLT2, also known as SLC5A2) are important mediators of epithelial …
SGLT2 (encoded by SGLT2, also known as SLC5A2) are important mediators of epithelial …
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional … - Diabetes …, 2022 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
the ADA's current clinical practice recommendations and is intended to provide the …
the ADA's current clinical practice recommendations and is intended to provide the …
[HTML][HTML] Effects of sotagliflozin added to insulin in patients with type 1 diabetes
SK Garg, RR Henry, P Banks, JB Buse… - … England Journal of …, 2017 - Mass Medical Soc
Background In most patients with type 1 diabetes, adequate glycemic control is not achieved
with insulin therapy alone. We evaluated the safety and efficacy of sotagliflozin, an oral …
with insulin therapy alone. We evaluated the safety and efficacy of sotagliflozin, an oral …
Emerging role of SGLT-2 inhibitors for the treatment of obesity
MJ Pereira, JW Eriksson - Drugs, 2019 - Springer
Abstract Sodium-glucose co-transporter 2 (SGLT2) inhibitors are glucose-lowering drugs
that reduce plasma glucose levels by inhibiting glucose and sodium reabsorption in the …
that reduce plasma glucose levels by inhibiting glucose and sodium reabsorption in the …
Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials
J Rosenstock, J Marquard, LM Laffel… - Diabetes …, 2018 - Am Diabetes Assoc
OBJECTIVE To evaluate the safety and efficacy of empagliflozin 10-and 25-mg doses plus a
unique lower dose (2.5 mg) as adjunct to intensified insulin in patients with type 1 diabetes …
unique lower dose (2.5 mg) as adjunct to intensified insulin in patients with type 1 diabetes …
International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium–glucose cotransporter (SGLT) inhibitors
T Danne, S Garg, AL Peters, JB Buse, C Mathieu… - Diabetes …, 2019 - Am Diabetes Assoc
Sodium–glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications
shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood …
shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood …